Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568776 · ClinicalTrials.gov registry record · Phase 2
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
- 20
- Study locations
NCT00568776 is a Phase 2 study of Alzheimer Disease that has completed, run by OPKO Health. The registered enrollment target is 353 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00568776, a Phase 2 study of Alzheimer Disease, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG ELND005
Study Locations (20)
Florida
- Brain Matters Research, Inc. - Delray Beach
- Sunrise Clinical Research, Inc - Hollywood
- Miami Jewish Home and Hospital For The Aged - Miami
- Avision Research Associates, LLC - Miami
- Compass Research, LLC - Orlando
- Roskamp Institute - Sarasota
- Neurology Clinical Research, Inc. - Sunrise
- University of South Florida Suncoast Alzheimer's and Gerontology Center - Tampa
- Premiere Research Institute - West Palm Beach
California
- Margolin Brain Institute - Fresno
- Collaborative NeuroScience Network, Inc. - Garden Grove
- UCLA Alzheimer's Disease Center, Dept. of Neurology - Los Angeles
- UC Irvine Medical Center - Orange
- UCSF Medical Center, Dept. of Neurology - San Francisco
Arizona
- Banner Alzheimer's Institute - Phoenix
- Sun Health Research Institute - Sun City
- University of Arizona, Health Sciences Center, Dept. of Neurology - Tucson
Connecticut
- Yale University School of Medicine, Alzheimer's Disease Research Unit - New Haven
District of Columbia
- Georgetown University Medical Center, Dept. of Neurology - Washington D.C.
Georgia
- Emory University, Dept. of Neurology - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568776
The ClinicalTrials.gov registry entry for NCT00568776 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Control is the first listed.
NCT00568776 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00568776 about?
NCT00568776 is a clinical study titled "ELND005 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
What is the current status of trial NCT00568776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2007-12. Estimated completion is 2010-05.
What conditions does trial NCT00568776 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT00568776?
The interventions under investigation include: Placebo Control (DRUG), ELND005 (DRUG).
Who is sponsoring clinical trial NCT00568776?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568776 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.